Iteos Therapeutics Inc

NASDAQ:ITOSUnited States

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.

Contact Information

Headquarters

321 Arsenal Street Bldg 312, Floor 3, Suite 301WATERTOWN, MA, United States 02472

Phone

857-204-4583

Fax

302-655-5049

Executives

Non-Executive Independent Chairman of the Board

David Hallal

President, Chief Executive Officer, Director

Michel Marcel Detheux

Chief Financial Officer

Matthew Gall

Chief Operating Officer

Matthew Call

Chief Scientific Officer

Yvonne Mcgrath